Founded in 2006 and acquired by ZOLL in 2021, ZOLL Respicardia is a leader in innovative technologies that address the unmet needs of people with Central Sleep Apnea (CSA). CSA results from the brain’s inability to send appropriate signals to the respiratory muscles to stimulate breathing during sleep. CSA is a serious breathing disorder that disrupts the normal breathing pattern and negatively affects quality of life and overall health. The remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for people with CSA.